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Abstract
Background: Artemisinin-based combinations are recommended for treatment of uncomplicated falciparum
malaria, but are costly and in limited supply. Clindamycin plus quinine is an alternative non-artemisinin-based
combination recommended by World Health Organization. The efficacy and safety of clindamycin plus quinine is
not known. This systematic review aims to assess the efficacy of clindamycin plus quinine versus other anti-malarial
drugs in the treatment of uncomplicated falciparum malaria.
Methods: All randomized controlled trials comparing clindamycin plus quinine with other anti-malarial drugs in
treating uncomplicated malaria were included in this systematic review. Databases searched included: Cochrane
Central Register of Controlled Trials, MEDLINE, EMBASE and LILACS. Two authors independently assessed study
eligibility, extracted data and assessed methodological quality. The primary outcome measure was treatment failure
by day 28. Dichotomous data was compared using risk ratio (RR), in a fixed effects model.
Results: Seven trials with 929 participants were included. Clindamycin plus quinine significantly reduced the risk of
day 28 treatment failure compared with quinine (RR 0.14 [95% CI 0.07 to 0.29]), quinine plus sulphadoxine-
pyrimethamine (RR 0.17 [95% CI 0.06 to 0.44]), amodiaquine (RR 0.11 [95% CI 0.04 to 0.27]), or chloroquine (RR 0.11
[95% CI 0.04 to 0.29]), but had similar efficacy compared with quinine plus tetracycline (RR 0.33 [95% CI 0.01 to
8.04]), quinine plus doxycycline (RR 1.00 [95% CI 0.21 to 4.66]), artesunate plus clindamycin (RR 0.57 [95% CI 0.26 to
1.24]), or chloroquine plus clindamycin (RR 0.38 [95% CI 0.13 to 1.10]). Adverse events were similar across treatment
groups but were poorly reported.
Conclusion: The evidence on the efficacy of clindamycin plus quinine as an alternative treatment for
uncomplicated malaria is inconclusive. Adequately powered trials are urgently required to compare this
combination with artemisinin-based combinations.
Background
Malaria is a disease of global public health importance,
caused by protozoan parasites of the genus Plasmodium.
T h ee p i d e m i o l o g yo fm a l a r i ai sr a p i d l yc h a n g i n ga n d
elimination may be feasible in some endemic regions
within the next decade. Over 90% of the malaria burden
is borne by populations in sub-Saharan Africa where
Plasmodium falciparum is predominant and the high
risk groups include young children and pregnant
women [1]. In the absence of a vaccine, chemotherapy
plus vector control remain the main tools for reducing
malaria-related morbidity and mortality in Africa. Some
studies linked the emergence of anti-malarial (specifi-
cally, chloroquine) drug resistance to an increased inci-
dence of severe malarial anaemia and malaria-related
mortality [2-5].
Artemisinin-based combination therapy (ACT) is the
recommended standard of care in the treatment of
uncomplicated falciparum malaria [6,7]. The adoption of
combination therapy -the simultaneous administration
of two or more blood schizontocidal drugs with inde-
pendent modes of action and different biochemical tar-
gets in the parasite - is thought to improve treatment
efficacy and to delay the emergence of drug resistance
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However, the implementation of ACT policy in the Afri-
can public health sector is challenged by limited avail-
ability (resulting in frequent stock-outs), inaccessibility
and high cost of the drugs [10]. The situation may be
improving due to increased financial and technical sup-
port from global initiatives, such as the Global Fund for
AIDS, TB and Malaria, and the Affordable Medicines
for Malaria. In some settings, the effective implementa-
tion of ACT for malaria treatment and insecticide-trea-
ted bed nets for vector control has already resulted in
substantial reductions of malaria-related morbidity, mor-
tality and admissions [11-14]. ACT resistance has been
described and global efforts are underway to contain the
evolution of artemisinin resistance [15,16]. Alternative
combinations to ACT are necessary and should be
assessed for efficacy and safety. Clindamycin plus qui-
nine is a potential non-ACT combination recommended
by World Health Organization (WHO)[7].
Clindamycin is a lincosamide antibiotic with anti-malar-
ial activities. It is used for the treatment of anaerobic and
gram positive bacterial infections, toxoplasmosis, babesio-
sis, and Pneumocystis carinii pneumonia. The drug is
available in formulations suitable for oral (as capsules or
oral suspension), or for parenteral administration. Clinda-
mycin is effective against P. falciparum, even as monother-
apy, but it is a slow-acting drug with a mean parasite
clearance time of four to six days and a mean fever clear-
ance time of three to five days. When used as monother-
apy, it must be given twice daily for at least 5 days. In
general, clindamycin is a well-tolerated drug with mild
and transient side effects. Initial studies described an asso-
ciation linking clindamycin therapy with a diarrhoeal ill-
ness due to Clostridium difficile, but this is rare and the
most frequent side effects include anorexia, nausea, vomit-
ing and abdominal discomfort [17].
Quinine is a fast-acting drug with a short elimination
half-life that has been recommended for the treatment
of severe malaria (in all age groups), for uncomplicated
malaria in pregnant women and for drug-resistant
malaria for almost 400 years [18]. Quinine is available as
an oral, rectal or parenteral formulation and is adminis-
tered eight hourly per day for 7 days [19]. The most fre-
quent adverse event associated with quinine treatment is
cinchonism, which is characterized by tinnitus, nausea,
headache and blurred vision. Combinations of quinine
with some antibiotics (e.g., tetracycline, doxycyline, clin-
damycin and azithromycin) significantly improved the
treatment efficacy compared to quinine alone in the
treatment of drug-resistant malaria [20-22]. The contin-
ued use of quinine is however challenged by poor toler-
ability and poor compliance associated with the
duration of treatment and the complex dosing regimes
[23,24].
Clindamycin plus quinine qualifies as an anti-malarial
drug combination because both drugs have potent anti-
malarial properties but different mechanisms of action
and the relatively fast-action of quinine can overcome
the drawback arising from the slow-action of clindamy-
cin. In combination with clindamycin, the treatment
course for quinine can be shortened to 3 days, which
may improve adherence, making this combination a
more practical and efficient option to consider for the
treatment of uncomplicated malaria [25]. In addition,
this combination can be administered to both children
and pregnant women (in all the three trimesters).
However, it is unclear whether this combination can
be a safe and effective alternative to ACT. In the
a b s e n c eo fe v i d e n c ef r o masystematic review, the
malaria treatment guidelines by WHO have recom-
mended clindamycin plus quinine as the drug of choice
for treatment of malaria infection in the first trimester
of pregnancy and as a second-line anti-malarial drug for
other cases, based on consensus opinion [7]. The objec-
tive of this systematic review was to assess the available
evidence on the efficacy and safety of clindamycin plus
quinine compared to other anti-malarial drugs (alone or
in combination) when used for treating adults and chil-
dren with uncomplicated falciparum.
Methods
Search strategy and selection criteria
Studies were considered for inclusion in the review if
they were randomized controlled trials designed to com-
pare the efficacy of clindamycin plus quinine with
another anti-malarial drug (used alone or in combina-
tion) in participants with symptomatic, microscopically-
confirmed uncomplicated falciparum malaria. Studies
that had enrolled participants with signs of severe
m a l a r i aw e r ee x c l u d e d .T h er e v i e w ’s primary outcome
was prospectively defined as parasitological treatment
failure evaluated 28 days after starting treatment. Sec-
ondary outcomes included day 14 parasitological failure,
gametocyte carriage, parasite and fever clearance time,
mean haemoglobin and adverse events.
Using a combination of the terms, “malaria”,” quinine”,
“clindamycin” or” dalacin”, a search of the following elec-
tronic databases was made: Cochrane Infectious Diseases
Group specialized register; Cochrane Central Register of
Controlled Trials (CENTRAL), published in The
Cochrane Library 2011, Issue 3; MEDLINE (1966 to
October 2011); EMBASE (1988 to October 2011); and
LILACS (1982 to October 2011). The third, fourth and
fifth MIM Pan-African Malaria Conference proceedings
were also searched for relevant abstracts. Individual
researchers working in the field, organizations including
WHO and the East African Network for Monitoring
Antimalarial Treatment (EANMAT), and pharmaceutical
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Rhône-Poulenc Rorer were contacted for unpublished
and ongoing trials. The reference lists of retrieved studies
were also checked for additional studies. An attempt was
made to retrieve all relevant trials regardless of language
or publication status (published, unpublished, in press,
and in progress).
Data extraction and management
Abstracts obtained by the search strategy were screened
for potentially relevant trials. Full text articles of the
selected trial reports were retrieved. Each trial report
was scrutinized for multiple publications from the same
data set. If a trial was published more than once, only
one publication was assessed. Based on the inclusion
criteria, both authors independently assessed the trials
for inclusion in the review. For the included trials, data
on trial dates, location, publication status, trial methods,
participants, interventions and outcomes was indepen-
dently extracted by both authors onto data abstraction
forms. Any disagreements were resolved by referring to
the study report and by discussion. Additional informa-
tion was sought from the trial authors if the available
data was insufficient or missing.
Data was extracted to allow for an intention-to-treat
analysis. For dichotomous outcome, the number of par-
ticipants experiencing the event and the number ana-
lysed in each treatment group was recorded. For
continuous outcome measures (e.g. fever and parasite
clearance times), the arithmetic means and standard
deviations for each group was extracted in addition to
the numbers analysed in each group. The range was
extracted if medians were reported.
Assessment of the methodological quality of included
studies
The methodological quality for each included trial was
independently assessed by both authors. Specifically, the
following components of methodological quality were
assessed: generation of allocation sequence, allocation con-
cealment, blinding and loss to follow up. Generation of
allocation sequence and allocation concealment were clas-
sified as adequate, inadequate, or unclear [26]. Blinding
was classified as open, single, or double blind. The percen-
tage of randomized participants lost to follow up was cal-
culated, and the percentage of participants available for
analysis was categorized as adequate, if it was at least 90%.
Data analysis
Data was analysed using Review Manager 5.1 software.
Dichotomous data was combined using risk ratios (RR),
while continuous data was combined using the weighted
mean difference (WMD). Where arithmetic means were
reported for an outcome measure where the scale is
naturally bound at zero, the ratio of the mean to the
standard deviation was used to check the assumption
that the data are normally distributed. When data was
suspected to be skewed or inappropriately summarized
as means and standard deviations (mean/sd > 2) then it
was not combined in a meta-analysis. The results are
presented as point estimates together with the 95% con-
fidence intervals. P values less than 0.05 were considered
statistically significant differences. A fixed effects model
was used in pooling data where there was no evidence
of heterogeneity.
Statistical heterogeneity was assessed by visually
inspecting the forest plots (for overlapping confidence
intervals), applying the chi-square test (p value < 0.10
considered statistically significant), and the I
2 statistic
with the value of 50% used to denote moderate levels of
heterogeneity [27]. If heterogeneity was detected, and if
it was still appropriate to pool the data, then a random-
effects model was used [28]. Potential sources of hetero-
g e n e i t yw e r ee x p l o r e db yc o n d u c t i n gs u b g r o u pa n a l y s e s
using participant age (less than versus greater or equal
to 5 years), and the effect of different drug dosing
regimes on treatment efficacy. A sensitivity analysis was
performed using allocation concealment to evaluate the
robustness of our conclusions.
Results
Description of included studies
Seventeen potentially relevant titles were found. Five
articles were immediately excluded at the initial screen-
ing stage because they did not meet the inclusion cri-
teria. Four other trials were excluded because they had
no comparison groups [29-32], and one because it had
assessed only safety outcomes and did not report effi-
cacy data [33].
This review is based on the seven randomized trials
that met the study inclusion criteria. The eligible trials
had enrolled 929 participants and had been conducted
between 1987 and 2004 in Gabon [34-36], Thailand
[37,38], France [39] and Brazil [40]. Of the 929 partici-
pants randomized in these trials, 826 (88.9%) were
included in the analysis, indicating an overall attrition
rate of 11% (range 1.5 to 21%).
All the included trials had enrolled participants with
microscopically-confirmed P. falciparum infection.
Adult participants were studied in all the trials, except
for two trials from Gabon, where children were enrolled
[34,36]. Of the five trials with adult participants, one
had enrolled travellers returning from the tropics [39],
while the other had enrolled pregnant women [38]. The
trials varied in their definition for when adult age began:
14 years in one trial [40], 15 years in two trials [35,39]
and unspecified in two trials [37,38]. The ages of the
e n r o l l e dc h i l d r e nr a n g e df r o mt h r e et o1 2y e a r si no n e
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ple size for the included trials was generally small, ran-
ging from 100 to 204 participants.
In three trials, the study design included three parallel
treatment arms in which clindamycin plus quinine was
compared with: quinine alone or quinine plus doxycycline
[35], quinine alone or quinine plus tetracycline [37]; amo-
diaquine alone or quinine plus sulphadoxine-pyrimetha-
mine [40]. In two trials, clindamycin plus quinine was
compared with artesunate alone [38], or clindamycin plus
artesunate [36]. In one trial [39], intravenous quinine plus
intravenous clindamycin was compared with intravenous
quinine followed by oral quinine. The last trial had four
treatment arms, in which clindamycin plus quinine was
compared with quinine alone, chloroquine alone, or a
combination of chloroquine plus clindamycin [34].
In four trials, clindamycin plus quinine was adminis-
tered every 12 h for 3 days [34-36,40]. Clindamycin plus
quinine was administered every 8 hours for 3 days in
one trial [39], and for seven days in another trial [38].
In the last trial, clindamycin was given every six hours,
while quinine was administered every 8 hours, for 7
days [37]. Overall, treatment duration ranged from 3 to
7 days, and the total daily dose for clindamycin ranged
from 10 to 30 mg/kg per day.
The duration of follow up was 28 days after initiation
of treatment in six trials [34-37,39,40] and 42 days in
one trial [38]. The primary endpoint was defined as day
28 parasitological failure in five trials [34,35,37,39,40],
day 28 parasitological cure (polymerase chain reaction
[PCR]-corrected) in one trial [36] and day 42 parasitolo-
gical failure (PCR-corrected) in one trial [38]. All the
seven trials reported on parasite clearance time and
adverse events, three trials reported on fever clearance
time [36,37,39], two trials on day 14 parasitological fail-
ure [34,35], two trials on the mean haemoglobin [36,38],
one trial on progression to severe anaemia [38], and two
trials on gametocyte carriage [36,38]. However, parasite
clearance time (PCT) and fever clearance time (FCT)
were not always consistently reported. Some trials
reported the mean PCT [35,36,38,40], while others
reported the median value [34,39]. Only one trial
reported the mean FCT [36].
Only two trials performed an intention-to-treat analy-
sis [36,39]. The remaining five trials reported outcomes
only for evaluable participants. Three trials revealed
their source of funding, including two that had received
funding from the Wellcome Trust of Great Britain
[37,38], and one, that had been funded by the local gov-
ernment in France [39]. Table 1 is a summary of the
characteristics of the included studies.
Methodological quality in the included studies
Only one trial described how the allocation sequence
was generated [36]. Three trials had adequate allocation
concealment [36,38,39] and were therefore considered of
high quality. In the remaining four trials, methods used
for allocation concealment were unclear [34,35,37,40].
Table 1 Characteristics of the included trials
Reference Location/dates Participants Interventions Outcomes
40 Brazil
(1987)
Adults
(> 14 yrs)
Quinine +clindamycin [1] Amodiaquine (AQ)
Quinine + SP
Day 28 parasite failure, PCT, adverse events
34 Gabon
(1992)
Children
(4-15 yrs)
Quinine+clindamycin [2]
Quinine
Chloroquine (CQ)
CQ + clindamycin
Day 28 parasite failure, Day 14 parasite failure, PCT,
adverse events
35 Gabon
(1993-1994)
Adults
(> 15 yrs)
Quinine + clindamycin [2]
Quinine
Quinine + doxycycline (Dx)
Day 28 parasite failure, Day 14 parasitological failure,
PCT, adverse events
37 Thailand (1995-
1997)
Adult males Quinine +clindamycin [3]
Quinine
Quinine + tetracycline (Tx)
Day 28 parasite failure, PCT, FCT, adverse events
39 France (1996-
1998)
Returning
travelers
Quinine +clindamycin [4]
Quinine
Day 28 parasite failure, PCT, FCT, adverse events
38 Thailand (1997-
2000)
Pregnant
women
Quinine + Clindamycin [5] Artesunate (AS) Day 42 parasite failure, mean Hb, gametocyte carriage,
adverse events
36 Gabon (2003-
2004)
Children
(3-12 yrs)
Quinine+clindamycin [6]
Artesunate (AS2)+ clindamycin
Day 28 parasite failure, PCT, FCT, mean Hb, adverse
events
Dosages: AQ: 25 mg/kg over 3 doses; CQ: 25 mg/kg over 3 days; SP: 500 mg/25 mg as single dose; AS: 12 mg/kg over 5 days; AS2: 2 mg/kg every 12 h for 6
doses; Dx: 2 mg/kg every 12 h for 6 doses; Tx: 4 mg/kg every 6 h for 7 days
[1] Quinine: 10 mg/kg every 12 h for 6 doses; clindamycin: 10 mg/kg every 12 h for 6 doses
[2] Quinine: 12 mg/kg every 12 h for 6 doses; clindamycin: 5 mg/kg every 12 h for 6 doses
[3] Quinine: 10 mg/kg every 8 h for 7 d; clindamycin 5 mg/kg every 6 h for 7 days
[4] Quinine: 8 mg/kg every 8 h for 3 days: clindamycin 5 mg/kg every 8 h for 3 days
[5] Quinine: 15 mg/kg every 12 h for 6 doses; clindamycin 7 mg/kg every 12 h for 6 doses
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come assessors adequately blinded using a double-blind
and placebo-controlled design [39]. Two trials were
open-label, suggesting that the patients and the provi-
ders were not blinded to the treatment assignment, but
it was unclear in these trials whether the outcome asses-
sors were also blinded [35,36]. In four trials, it was
unclear if any attempt was made to blind the partici-
pants, providers or outcome assessors, as there was no
mention of blinding in these trials [34,37,38,40].
Loss to follow up was below 10% in four trials
[34,36,38,39]. The remaining three trials [35,37,40]
excluded between 10 to 21% of study participants from
analysis. Table 2 is a summary of the methodological
quality assessment of the included studies.
Efficacy of clindamycin plus quinine versus other anti-
malarial drugs
There were nine comparisons between clindamycin plus
quinine and the different control treatments. Figure 1 is
a summary of the parasitological failure risks on day 28
between clindamycin plus quinine in comparison with
the control treatments.
Clindamycin plus quinine versus quinine
In four trials [34,35,37,39], the proportion of partici-
pants experiencing parasitological failure on day 28 was
significantly lower among those treated with clindamy-
cin plus quinine compared with those treated with qui-
nine (RR 0.14, 95% CI 0.07 to 0.29; 406 participants).
PCR adjusted failure rates were significantly lower in
those treated with clindamycin plus quinine compared
to those treated with quinine alone (RR 0.13, 95%CI
0.04 to 0.40; 80 participants) in one trial [35]. In two
trials [34,35], a significantly higher proportion of partici-
pants treated with quinine had parasitological failure on
day 14 compared to those treated with clindamycin plus
quinine (RR 0.08, 95% CI 0.01 to 0.63; 158 participants).
Figure 2 is a summary of the participants with day 14
parasitological failure. There was no evidence of hetero-
geneity between these trials (I
2 = 0%). In one trial [37],
the mean parasite clearance time was similar between
participants treated with clindamycin plus quinine com-
pared to those treated with quinine alone (WMD 2.0,
95% CI -5.61 to 9.61; 136 participants).
Clindamycin plus quinine versus chloroquine
One trial [34], compared clindamycin plus quinine with
chloroquine in 71 participants. The risk of parasitologi-
cal failure by day 28 was significantly lower among
those treated with clindamycin plus quinine compared
to those treated using chloroquine (RR 0.11, 95% CI
0.04 to 0.29). Similarly, the risk day 14 parasitological
failure was significantly lower among participants on the
clindamycin plus quinine compared with those in the
chloroquine arm (RR 0.02, 95%CI 0.0 to 0.37). The med-
ian parasite clearance time was significantly longer in
the chloroquine arm compared to the clindamycin plus
quinine arm: 5.5 vs 3 days, respectively.
Clindamycin plus quinine versus amodiaquine
In one trial [40], clindamycin plus quinine was com-
pared with amodiaquine in 75 participants. Compared
to amodiaquine, the risk of parasitological failure by day
28 was significantly lower among those treated with
clindamycin plus quinine (RR 0.11, 95% CI 0.04 to 0.27).
The mean parasite clearance times were not statistically
significantly different between the two regimes: 86.4 vs
82.7 h for clindamycin plus quinine vs amodiaquine,
respectively.
Clindamycin plus quinine versus artesunate
No participant failed treatment by day 28 in the single
trial [38], which evaluated clindamycin plus quinine in
comparison of with artesunate for the treatment of 131
pregnant women with uncomplicated falciparum malaria
in Thailand. The parasite clearance time was signifi-
cantly longer for participants treated with clindamycin
plus quinine compared with those treated using artesu-
nate (WMD 14.4 95%CI 14.03 to 14.77). However, a sig-
nificantly higher proportion of participants developed
gametocytes after treatment with clindamycin plus qui-
nine compared with artesunate (RR 2.90, 95% CI 1.13 to
7.47). At the end of day 42 follow up, participants
Table 2 Risk of bias in the included trials
Study Allocation sequence Allocation concealment Blinding Number randomized Loss to follow up N (%)
Kremsner 1988 Unclear Unclear Unclear 115 20 (17.4)
Kremsner 1994 Unclear Unclear Unclear 144 14 (9.7)
Metzger 1995 Unclear Unclear Open 120 12 (10)
Pukrittayakamee 2000 Unclear Unclear Unclear 204 43 (21)
Parola 2001 Unclear Adequate Double 115 7 (6.1)
McGready 2001 Unclear Adequate Unclear 131 2 (1.5)
Ramharter 2005 Adequate Adequate Open 100 5 (5)
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cantly lower mean haemoglobin compared to those trea-
ted with artesunate (WMD 0.66, 95% CI 0.18 to 1.14;
129 participants).
Clindamycin plus quinine versus quinine plus
sulphadoxine/pyrimethamine
In one trial [40], the risk of parasitological failure by day
28 was significantly lower among those treated with
Study or Subgroup
1.1.1 Clindamycin plus quinine vs Quinine
Kremsner 1994
Metzger 1995
Parola 2001
Pukrittayakamee 2000
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.53, df = 3 (P = 0.91); I² = 0%
Test for overall effect: Z = 5.49 (P < 0.00001)
1.1.2 Clindamycin plus quinine vs Chloroquine
Kremsner 1994
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 4.57 (P < 0.00001)
1.1.3 Clindamycin plus quinine vs Amodiaquine
Kremsner 1988
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 4.64 (P < 0.00001)
1.1.4 Clindamycin plus quinine vs Quinine + SP
Kremsner 1988
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 3.59 (P = 0.0003)
1.1.5 Clindamycin plus quinine vs Quinine plus Tetracycline
Pukrittayakamee 2000
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
1.1.6 Clindamycin plus quinine vs Quinine plus Doxycycline
Metzger 1995
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
1.1.7 Clindamycin plus quinine vs Chloroquine + clindamycin
Kremsner 1994
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.78 (P = 0.08)
1.1.8 Clindamycin plus quinine vs Artesunate + clindamycin
Ramharter 2005
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Events
4
3
0
0
7
4
4
4
4
4
4
0
0
3
3
4
4
8
8
Total
39
40
57
68
204
39
39
46
46
46
46
68
68
40
40
39
39
50
50
Events
21
23
2
7
53
29
29
24
24
21
21
1
1
3
3
10
10
14
14
Total
36
40
58
68
202
32
32
29
29
40
40
68
68
40
40
37
37
50
50
Weight
39.8%
42.0%
4.5%
13.7%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
M-H, Fixed, 95% CI
0.18 [0.07, 0.46]
0.13 [0.04, 0.40]
0.20 [0.01, 4.15]
0.07 [0.00, 1.14]
0.14 [0.07, 0.29]
0.11 [0.04, 0.29]
0.11 [0.04, 0.29]
0.11 [0.04, 0.27]
0.11 [0.04, 0.27]
0.17 [0.06, 0.44]
0.17 [0.06, 0.44]
0.33 [0.01, 8.04]
0.33 [0.01, 8.04]
1.00 [0.21, 4.66]
1.00 [0.21, 4.66]
0.38 [0.13, 1.10]
0.38 [0.13, 1.10]
0.57 [0.26, 1.24]
0.57 [0.26, 1.24]
Clindamycin plus quinine Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours Clin+Quinine Favours control
Figure 1 Day 28 parasitological failure.
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using quinine plus sulphadoxine/pyrimethamine (RR
0.17, 95% CI 0.06 to 0.44; 86 participants). The mean
parasite clearance time was significantly longer with
clindamycin plus quinine compared with quinine plus
SP: 86.4 vs 78.2 h, p < 0.01.
Clindamycin plus quinine versus quinine plus tetracycline
A similar risk of day 28 parasitological treatment failure
was observed between those treated with clindamycin
plus quinine compared to those treated using quinine
plus tetracycline (RR 0.33, 95% CI 0.01 to 8.04; 136 par-
ticipants) in one trial [37]. There was no difference in
the mean parasite clearance time, 79 ± 20 vs. 77 ± 23 h,
respectively. Similarly, the median FCT was comparable
between the treatment arms, 8 (2-95) hours in the clin-
damycin plus quinine and 8 (3-36) hours in the quinine
plus tetracycline arm, respectively.
Clindamycin plus quinine versus quinine plus doxycycline
There was no difference in the risk of parasitological
failure by day 28 when those treated with clindamycin
plus quinine were compared to those treated using qui-
nine plus doxycycline (RR 1.00, 95% CI 0.21 to 4.66; 80
participants). The mean parasite clearance time was
similar between the two treatment regimes: 57.8 vs 52.8
h, respectively [35].
Clindamycin plus quinine versus chloroquine plus
clindamycin
The risk of parasitological failure by day 28 was not
significantly different between those treated with clin-
damycin plus quinine compared to those treated with
chloroquine plus clindamycin (RR 0.38, 95% CI 0.13 to
1.10; 76 participants) in one trial [34]. No participants
failed therapy by day 14 on either arm. The median
parasite clearance time was significantly shorter in
Study or Subgroup
1.2.1 Clindamycin plus quinine vs quinine
Kremsner 1994
Metzger 1995
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.01, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 2.42 (P = 0.02)
1.2.2 Clindamycin plus quinine vs Chloroquine
Kremsner 1994
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 2.66 (P = 0.008)
1.2.3 clindamycin plus quinine vs quinine plus doxycycline
Metzger 1995
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Not applicable
1.2.4 clindamycin plus quinine vs chloroquine plus clindamycin
Kremsner 1994
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Not applicable
Events
0
0
0
0
0
0
0
0
0
Total
39
40
79
39
39
40
40
39
39
Events
5
6
11
21
21
0
0
0
0
Total
39
40
79
39
39
40
40
39
39
Weight
45.8%
54.2%
100.0%
100.0%
100.0%
M-H, Fixed, 95% CI
0.09 [0.01, 1.59]
0.08 [0.00, 1.32]
0.08 [0.01, 0.63]
0.02 [0.00, 0.37]
0.02 [0.00, 0.37]
Not estimable
Not estimable
Not estimable
Not estimable
Clindamycin plus quinine Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours Clin+quinine Favours control
Figure 2 Day 14 parasitological failure.
Obonyo and Juma Malaria Journal 2012, 11:2
http://www.malariajournal.com/content/11/1/2
Page 7 of 11the clindamycin plus quinine arm, 4 vs. 3 days,
respectively.
Clindamycin plus quinine versus artesunate plus
clindamycin
Compared to artesunate plus clindamycin, comparable
proportion of participants experienced parasitological
failure on day 28 (RR 0.57, 95% CI 0.26 to 1.24), after
PCR adjustment (RR 0.50, 95% CI 0.13 to 1.89) and
similar proportions had gametocyte carriage (RR 2.50,
95% CI 0.51 to 12.29) after treatment with clindamycin
plus quinine. Participants treated with clindamycin plus
quinine had similar fever clearance time (WMD 9.0,
95% CI 0.78 to 17.22) and mean haemoglobin concen-
tration (WMD 0.20, 95% CI -0.35 to 0.75) but signifi-
cantly longer mean parasite clearance time (WMD
16.70, 95%CI 10.99 to 22.41) compared with those trea-
ted using artesunate plus clindamycin [36].
Subgroup analysis
To investigate the effect of dosing regimens on parasito-
logical failure by day 28, a sub-group analysis was per-
formed for the comparisons between clindamycin plus
quinine vs. quinine.
In the two trials [34,35] where participants received
the 12 hourly regime for 3 days, clindamycin plus
quinine significantly reduced the risk of parasitological
failure compared with quinine (RR 0.15, 95% CI 0.07 to
0.32; 155 participants). However, the risk of treatment
failure was not significantly different between clindamy-
cin plus quinine compared to quinine in the one trial
[39] that evaluated the eight hourly treatment regime
for 3 days (RR 0.20, 95% CI 0.01 to 4.15; 115 partici-
pants) or in the other trial [37] that evaluated the 6-
hourly regimen for 7 days (RR 0.07, 95% CI 0.00 to 1.14;
136 participants). Figure 3 is a summary of the effect of
dosing regimes on day 28 parasitological failure.
Sensitivity analysis
Meta-analysis for the primary outcome was repeated
separately using trials with adequate or unclear alloca-
tion concealment. This analysis was possible only for
the comparison between clindamycin plus quinine com-
pared with quinine monotherapy. There was no differ-
ence in the risk of treatment failure between
clindamycin plus quinine compared with quinine by day
28 in the one trial [39] with adequate allocation conceal-
ment (RR 0.20, 95% CI 0.01 to 4.15; 115 participants).
However, in the three trials [34,35,37] with unclear allo-
cation concealment, treatment with clindamycin plus
quinine significantly reduced the risk of treatment fail-
ure (RR 0.14, 95% CI 0.07 to 0.29; 291 participants).
Study or Subgroup
1.3.1 Clin+quinine vs Quinine: 3-day 12 hourly regimen
Kremsner 1994
Metzger 1995
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.16, df = 1 (P = 0.69); I² = 0%
Test for overall effect: Z = 5.02 (P < 0.00001)
1.3.2 Clin+quinine vs Quinine: 3-day 8 hourly regimen
Parola 2001
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
1.3.3 Clin+quinine vs Quinine: 7-day 6 hourly regimen
Pukrittayakamee 2000
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.87 (P = 0.06)
Events
4
3
7
0
0
0
0
Total
39
40
79
57
57
68
68
Events
21
23
44
2
2
7
7
Total
36
40
76
58
58
68
68
Weight
48.7%
51.3%
100.0%
100.0%
100.0%
100.0%
100.0%
M-H, Fixed, 95% CI
0.18 [0.07, 0.46]
0.13 [0.04, 0.40]
0.15 [0.07, 0.32]
0.20 [0.01, 4.15]
0.20 [0.01, 4.15]
0.07 [0.00, 1.14]
0.07 [0.00, 1.14]
Clindamycin plus quinine Quinine Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours Clin+Quinine Favours Quinine
Figure 3 Effect of treatment dosing on day 28 parasitological failure.
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Page 8 of 11Figure 4 is a summary of the effect of allocation con-
cealment on treatment efficacy.
Adverse events
All the seven trials reported on adverse events. Four
[36,38-40] of the seven trials described how adverse
events were defined and assessed. Over all, five partici-
pants in two trials [39,40] experienced serious adverse
events: watery diarrhoea due to C. difficile (two partici-
pants, treated with clindamycin plus quinine), severe
haemolytic anaemia (one participant, treated with qui-
nine), severe toxic rash (one participant, treated with
quinine) and erythematous rash (one participant, treated
with quinine plus SP). All the other adverse events were
described as mild and transient.
Discussion
This review summarizes the evidence from seven rando-
mized controlled trials on the efficacy of clindamycin
plus quinine in comparison with other anti-malarial
drugs in the treatment of participants with uncompli-
cated falciparum malaria. The review aimed to deter-
mine whether clindamycin plus quinine is an effective
and safe alternative for the ACT in the treatment of
uncomplicated falciparum malaria. About 930 patients
participated in the trials included in the review. Most of
the included trials had relatively small sample sizes. A
wide range of drugs were used in the comparisons and
treatment regimens were often not similar.
This review had some limitations. Allocation conceal-
ment is an important measure of a trial’s methodological
quality. Only three trials adequately described their
methods for allocation concealment. The risk of bias
was therefore uncertain in four trials that did not
describe these methods. Similarly, four trials did not
clearly describe their blinding procedures and in three
trials the rate of attrition was at least 10%, also suggest-
ing a possible risk of bias. The reason for attrition was
simply stated as loss to follow up–rendering it difficult
to attribute to an effect of the interventions. Only two
trials performed an intention-to-treat analysis [36,39].
Data was scarce for most comparisons, suggesting that
this review may lack power to detect some differences.
The primary outcome of this review is based on crude
estimates of treatment failure. In malaria treatment
trials, the true failure risk is best evaluated using the
PCR technique, which distinguishes recrudescent (resis-
tant) from new infections. In this review, only two trials
used PCR to determine the treatment efficacy. Most
trials had multiple arms and many treatment compari-
sons were derived from single trials. The available data
was outdated and most of the studies were done with
anti-malarial drugs that have long been phased out.
Only one trial compared the efficacy of clindamycin
plus quinine with an artesunate-based combination,
albeit not a WHO-recommended ACT.
Within the mentioned limitations, the risk of parasito-
logical failure by 28 days was significantly lower in parti-
cipants treated with clindamycin plus quinine compared
to quinine, amodiaquine, chloroquine, or quinine plus
SP. A similar risk of treatment failure was noted
between clindamycin plus quinine and quinine plus
Study or Subgroup
1.4.1 Clin+quinine vs Quinine: Adequate allocation concealment
Parola 2001
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
1.4.2 Clin+quinine vs Quinine: Unclear Allocation concealment
Kremsner 1994
Metzger 1995
Pukrittayakamee 2000
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.49, df = 2 (P = 0.78); I² = 0%
Test for overall effect: Z = 5.40 (P < 0.00001)
Events
0
0
4
3
0
7
Total
57
57
39
40
68
147
Events
2
2
21
23
7
51
Total
58
58
36
40
68
144
Weight
100.0%
100.0%
41.7%
43.9%
14.3%
100.0%
M-H, Fixed, 95% CI
0.20 [0.01, 4.15]
0.20 [0.01, 4.15]
0.18 [0.07, 0.46]
0.13 [0.04, 0.40]
0.07 [0.00, 1.14]
0.14 [0.07, 0.29]
Clindamycin plus quinine Quinine Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours Clin+Quinine Favours Quinine
Figure 4 Effect of allocation concealment on day 28 parasitological failure.
Obonyo and Juma Malaria Journal 2012, 11:2
http://www.malariajournal.com/content/11/1/2
Page 9 of 11tetracycline, quinine plus doxycycline, artesunate plus
clindamycin, and chloroquine plus clindamycin. The
addition of clindamycin to quinine (compared to qui-
nine monotherapy), improved treatment efficacy, shor-
tened the duration of treatment and reduced the risk of
treatment failure. In comparison to quinine alone, the
combination consistently reduced the risk of treatment
failure by 86%, with a 95% confidence interval ranging
from 71 to 93%. Quinine is still considered highly effec-
tive in sub-Saharan Africa, but a decline in the sensitiv-
ity of quinine has been reported from several endemic
areas suggesting that quinine resistance may already be
present [41-44]. There are concerns that the emergence
o fq u i n i n er e s i s t a n c em a yc o m p r o m i s et h ee f f i c a c yo f
this combination.
In all the trials reviewed, the combination appeared
safe and serious adverse events were rare. However, the
reporting of adverse event details was generally poor.
The rapidity with which an anti-malarial drug relieves
fever and clears parasites is an important consideration
for ensuring treatment adherence. Clindamycin plus qui-
nine was not consistently associated with shorter or
longer fever and parasite clearance times.
The second edition of the WHO guidelines for treat-
ment of malaria, recommends clindamycin plus qui-
nine as the drug of choice for treating malaria
infection in the first trimester of pregnancy and as a
second-line drug for treatment failures, for malaria in
the second and third trimesters of pregnancy, for tra-
vellers and for the oral phase of severe malaria treat-
ment [7]. These guidelines recommend that the
combination should be given for 7 days. This review
suggests that in comparison with quinine monother-
apy, a three-day course of clindamycin plus quinine
(administered every 12 h) may be as effective as a 7
d a yc o u r s ea tr e d u c i n gt h er i s ko fd a y2 8t r e a t m e n t
failure. However, further study and direct comparison
of dose regimens is required. The implementation of
this combination may be limited by the high cost of
clindamycin, the emerging evidence of quinine resis-
tance and by the co-administration of the drugs (cur-
rently not co-formulated). Compared to artemisinin-
based combination therapies, clindamycin plus quinine
has limited effect on gametocytes, although this could
be improved by adding primaquine to the therapy.
There was limited data for most comparisons, but this
review suggests that clindamycin plus quinine is an effec-
tive treatment alternative for uncomplicated falciparum
malaria that can safely be administered to both pregnant
women and children. Sufficient evidence was found to
indicate that clindamycin plus quinine is more effective at
reducing the risk of parasitological failure by day 28 com-
pared with quinine monotherapy. However, data is lacking
on the efficacy of clindamycin plus quinine in comparison
with artemisinin-based combinations for the treatment of
uncomplicated malaria or even for the treatment of
malaria in pregnancy. Adequately powered efficacy trials
are urgently required to determine the efficacy of the
three-day 12 hourly regimen of clindamycin plus quinine
in comparison to artemisinin-based combinations in the
treatment of uncomplicated malaria. Research is also
required to establish the role of clindamycin plus quinine
in the treatment of malaria in pregnancy. Better reporting
of trial methods (especially, allocation concealment) would
improve the interpretation of these future studies.
Acknowledgements
This document is an output from a project funded by the UK Department
for International Development (DFID) for the benefit of developing
countries. The views expressed in this review are however not necessarily
those of DFID. Charles Obonyo was awarded a Reviews for Africa Fellowship
http://www.mrc.ac.za/cochrane/rap.htm, funded by a grant from the Nuffield
Commonwealth Programme, through The Nuffield Foundation. This review
was developed during the Reviews for Africa Programme review completion
course organized by the South African Cochrane Centre, June 2006. We
thank the Director, Kenya Medical Research Institute, for permission to
publish these results.
Author details
1Centre for Global Health Research, Kenya Medical Research Institute, P.O.
BOX 1578, Kisumu 40100, Kenya.
2Division of Malaria Control, P.O. BOX
19982, Nairobi 00202, Kenya.
Authors’ contributions
COO developed the protocol, scanned the results of the literature search for
potentially relevant trials, assessed potentially relevant trials for inclusion into
the review, assessed the methodological quality of the included trials,
independently extracted the data, entered the data into Review Manager,
performed the statistical analysis, and drafted the manuscript. EAJ edited the
protocol, assessed potentially relevant trials for inclusion into the review,
assessed the methodological quality of the included trials and
independently extracted the data. Both authors read and approved the final
manuscript.
Conflict of interest
The authors declare that they have no competing interests.
Received: 30 June 2011 Accepted: 4 January 2012
Published: 4 January 2012
References
1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI: The global distribution
of clinical episodes of Plasmodium falciparum. Nature 2005, 434:214-217.
2. Trape JF, Pison G, Preziosi MP, Enel C, Desgrées du Loû A, Delaunay V,
Samb B, Lagarde E, Molez JF, Simondon F: Impact of chloroquine
resistance on malaria mortality. Comptes Rendus Acad Sci III 1998,
321:689-697.
3. Ekvall H, Premji Z, Björkman A: Chloroquine treatment for uncomplicated
childhood malaria in an area with drug resistance: early treatment
failure aggravates anaemia. Trans R Soc Trop Med Hyg 1998, 92:556-60.
4. Zucker JR, Ruebush TK, Obonyo C, Otieno J, Campbell CC: The mortality
consequences of the continued use of chloroquine in Africa: experience
in Siaya, western Kenya. Am J Trop Med Hyg 2003, 68:386-90.
5. Meerman L, Ord R, Bousema JT, van Niekerk M, Osman E, Hallett R,
Pinder M, Walraven G, Sutherland CJ: Carriage of chloroquine-resistant
parasites and delay of effective treatment increase the risk of severe
malaria in Gambian children. J Infect Dis 2005, 192:1651-1657.
6. World Health Organization: Antimalarial drug combination therapy World
Health Organization, Geneva;, Report of a WHO technical consultation, 4-5
April 2001 (WHO/CDS/RBM/2001.35).
Obonyo and Juma Malaria Journal 2012, 11:2
http://www.malariajournal.com/content/11/1/2
Page 10 of 117. World Health Organization: Guidelines for the treatment of malaria. Second
edition. WHO, Geneva, Switzerland; 2010.
8. White NJ, Olliaro PL: Strategies for the prevention of antimalarial drug
resistance: rationale for combination therapy for malaria. Parasitol Today
1996, 12:399-401.
9. White NJ: Antimalarial drug resistance and combination chemotherapy.
Philos Trans R Soc London B 1999, 354:739-749.
10. Whitty CJ, Chandler C, Ansah E, Leslie T, Staedke SG: Deployment of ACT
antimalarials for treatment of malaria: challenges and opportunities.
Malar J 2008, 7(Suppl 1):S7.
11. Otten M, Aregawi M, Were W, Karema C, Medin A, Bekele W, Jima D,
Gausi K, Komatsu R, Korenromp E, Low-Beer D, Grabowsky M: Initial
evidence of reduction of malaria cases and deaths in Rwanda and
Ethiopia due to rapid scale-up of malaria prevention and treatment.
Malar J 2009, 8:14.
12. Bhattarai A, Ali AS, Kachur SP, Mårtensson A, Abbas AK, Khatib R, Al-
Mafazy AW, Ramsan M, Rotllant G, Gerstenmaier JF, Molteni F, Abdulla S,
Montgomery SM, Kaneko A, Björkman A: Impact of artemisinin-based
combination therapy and insecticide-treated nets on malaria burden in
Zanzibar. PLoS Med 2007, 4:e309.
13. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, Dlamini SS,
Tsoka J, Bredenkamp B, Mthembu DJ, White NJ, Sharp BL: Effect of
artemether-lumefantrine policy and improved vector control on malaria
burden in KwaZulu-Natal, South Africa. PLoS Med 2005, 2:e330.
14. Okiro EA, Hay SI, Gikandi PW, Sharif SK, Noor AM, Peshu N, Marsh K,
Snow RW: The decline in paediatric malaria admissions on the coast of
Kenya. Malar J 2007, 6:151.
15. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F,
Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K,
Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N,
Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum
malaria. N Engl J Med 2009, 361:455-467.
16. WHO: Global plan for artemisinin resistance containment (GPARC) 2011
[http://www.who.int/malaria/publications/atoz/artemisinin_resistance_
containment_2011.pdf].
17. Wiström J, Norrby SR, Myhre EB, Eriksson S, Granström G, Lagergren L,
Englund G, Nord CE, Svenungsson B: Frequency of antibiotic-associated
diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective
study. J Antimicrob Chemother 2001, 47:43-50.
18. Meshnick SR: Why does quinine still work after 350 years of use? Parasitol
Today 1997, 13:89-90.
19. Kofoed PE, Ursing J, Rodrigues A, Rombo L: Failures following initial
treatment for uncomplicated malaria: quinine as second line therapy. J
Pediatr Infect Dis 2007, 2:121-126.
20. Bunnag D, Karbwang J, Na-Bangchang K, Thanavibul A, Chittamas S,
Harinasuta T: Quinine-tetracycline for multidrug resistant falciparum
malaria. Southeast Asian J Trop Med Public Health 1996, 27:15-18.
21. Ejaz A, Haqnawaz K, Hussain Z, Butt R, Awan ZI, Bux H: Treatment of
uncomplicated Plasmodium falciparum malaria with quinine-doxycycline
combination therapy. J Pak Med Assoc 2007, 57:502-505.
22. Miller RS, Wongsrichanalai C, Buathong N, McDaniel P, Walsh DS, Knirsch C,
Ohrt C: Effective treatment of uncomplicated Plasmodium falciparum
malaria with azithromycin-quinine combinations: a randomized, dose-
ranging study. Am J Trop Med Hyg 2006, 74:401-406.
23. Yeka A, Achan J, D’Alessandro U, Talisuna A: Quinine monotherapy for
treating uncomplicated malaria in the era of artemisinin-based
combination therapy: an appropriate public health policy? Lancet Infect
Dis 2009, 9:448-452.
24. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN,
Rosenthal PJ, D’Alessandro U: Quinine, an old anti-malarial drug in a
modern world: role in the treatment of malaria. Malar J 2011, 10:144.
25. Lell B, Kremsner PG: Clindamycin as an antimalarial drug: review of
clinical trials. Antimicrob Agent Chemother 2002, 46:2315-2320.
26. Juni B, Altman DG, Egger M: Systematic reviews of healthcare: assessing
the quality of controlled clinical trials. BMJ 2001, 323:42-46.
27. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis.
Stat Med 2002, 21:1539-1558.
28. DerSimonian R, Laird N: Meta-analysis in clinical trials. Contr Clin Trial 1986,
7:177-188.
29. Miller LH, Glew RH, Wyler DJ, Howard WA, Collins WE, Contacos PG,
Neva FA: Evaluation of clindamycin in combination with quinine against
multidrug-resistant strains of Plasmodium falciparum. Am J Trop Med Hyg
1974, 23:565-569.
30. Clyde DF, Gilman RH, McCarthy VC: Antimalarial effects of clindamycin in
man. Am J Trop Med Hyg 1975, 24:369-370.
31. Adehossi E, Parola P, Foucault C, Delmont J, Brouqui P, Badiaga S,
Ranque S: Three-day quinine-clindamycin treatment of uncomplicated
falciparum malaria imported from the tropics. Antimicrob Agent
Chemother 2003, 47:1173.
32. Vaillant M, Millet P, Luty A, Tshopamba P, Lekoulou F, Mayombo J,
Georges AJ, Deloron P: Therapeutic efficacy of clindamycin in
combination with quinine for treating uncomplicated malaria in a
village dispensary in Gabon. Trop Med Int Health 1997, 2:917-919.
33. Ranque S, Parola P, Adehossi E, Brouqui P, Delmont J: Mefloquine versus 3-
day oral quinine-clindamycin in uncomplicated imported falciparum
malaria. Trav Med Infect Dis 2007, 5:306-309.
34. Kremsner PG, Winkler S, Brandts C, Neifer S, Bienzle U, Graninger W:
Clindamycin in combination with chloroquine or quinine is effective
therapy for uncomplicated falciparum malaria in children from Gabon. J
Infect Dis 1994, 169:467-470.
35. Metzger W, Mordmüller B, Graninger W, Bienzle U, Kremsner PG: High
efficacy of short-term quinine-antibiotic combinations for treating adult
malaria patients in an area which malaria is hyperendemic. Antimicrob
Agent Chemother 1995, 39:245-246.
36. Ramharter M, Oyakhirome S, Klein Klouwenberg P, Adégnika AA,
Agnandji ST, Missinou MA, Matsiégui PB, Mordmüller B, Borrmann S, Kun JF,
Lell B, Krishna S, Graninger W, Issifou S, Kremsner PG: Artesunate-
clindamycin versus quinine-clindamycin in the treatment of Plasmodium
falciparum malaria: a randomized controlled trial. Clin Infect Dis 2005,
40:1777-1784.
37. Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S,
White NJ: Therapeutic response to quinine and clindamycin in
multidrug-resistant falciparum malaria. Antimicrob Agent Chemother 2000,
44:2395-2398.
38. McGready R, Cho T, Samuel , Villegas L, Brockman A, van Vugt M,
Looareesuwan S, White NJ, Nosten F: Randomized comparison of quinine-
clindamycin versus artesunate in the treatment of falciparum malaria in
pregnancy. Tran R Soc Trop Med Hyg 2001, 95:651-656.
39. Parola P, Ranque S, Badiaga S, Niang M, Blin O, Charbit JJ, Delmont J,
Brouqui P: Controlled trial of 3-day quinine-clindamycin treatment versus
7-day quinine treatment for adult travellers with uncomplicated
falciparum malaria imported from the tropics. Antimicrob Agent
Chemother 2001, 45:932-935.
40. Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM,
Wiedermann G: A comparative trial of three regimens for treating
uncomplicated falciparum malaria in Acre, Brazil. J Infect Dis 1988,
158:1368-1371.
41. Pukrittayakamee S, Supanaranond W, Looaresuwan S, Vanijanonta S,
White NJ: Quinine in severe falciparum malaria: evidence of declining
efficacy in Thailand. Trans R Soc Trop Med Hyg 1994, 88:324-327.
42. Adam I, Salih I, Elbashir MI: Quinine for the treatment of uncomplicated
Plasmodium falciparum malaria in eastern Sudan. Trans R Soc Trop Med
Hyg 2005, 99:736-738.
43. Adegnika AA, Breitling LP, Agnandji ST, Chai SK, Schütte D, Oyakhirome S,
Schwarz NG, Grobusch MP, Missinou MA, Ramharter M, Issifou S,
Kremsner PG: Effectiveness of quinine monotherapy for the treatment of
Plasmodium falciparum infection in pregnant women in Lambarene,
Gabon. Am J Trop Med Hyg 2005, 73:263-266.
44. Achan J, Tibenderana JK, Kyabayinze D, Wabwire Mangen F, Kamya MR,
Dorsey G, D’Alessandro U, Rosenthal PJ, Talisuna AO: Effectiveness of
quinine versus artemether-lumefantrine for treating uncomplicated
falciparum malaria in Ugandan children: randomized trial. BMJ 2009, 339:
b2763.
doi:10.1186/1475-2875-11-2
Cite this article as: Obonyo and Juma: Clindamycin plus quinine for
treating uncomplicated falciparum malaria: a systematic review and
meta-analysis. Malaria Journal 2012 11:2.
Obonyo and Juma Malaria Journal 2012, 11:2
http://www.malariajournal.com/content/11/1/2
Page 11 of 11